Swiss National Bank Acquires 38,400 Shares of Vaxcyte, Inc. (NASDAQ:PCVX)

Swiss National Bank grew its stake in shares of Vaxcyte, Inc. (NASDAQ:PCVX - Free Report) by 21.3% during the fourth quarter, according to the company in its most recent disclosure with the SEC. The fund owned 219,000 shares of the company's stock after buying an additional 38,400 shares during the quarter. Swiss National Bank owned approximately 0.18% of Vaxcyte worth $17,927,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors have also recently modified their holdings of PCVX. Whipplewood Advisors LLC bought a new stake in shares of Vaxcyte in the fourth quarter worth $28,000. Smartleaf Asset Management LLC grew its stake in shares of Vaxcyte by 188.4% in the fourth quarter. Smartleaf Asset Management LLC now owns 398 shares of the company's stock worth $33,000 after purchasing an additional 260 shares during the last quarter. Blue Trust Inc. grew its stake in shares of Vaxcyte by 100.0% in the fourth quarter. Blue Trust Inc. now owns 742 shares of the company's stock worth $61,000 after purchasing an additional 371 shares during the last quarter. Assetmark Inc. grew its stake in shares of Vaxcyte by 77,500.0% in the fourth quarter. Assetmark Inc. now owns 776 shares of the company's stock worth $64,000 after purchasing an additional 775 shares during the last quarter. Finally, Meeder Asset Management Inc. grew its stake in shares of Vaxcyte by 1,007.9% in the third quarter. Meeder Asset Management Inc. now owns 698 shares of the company's stock worth $80,000 after purchasing an additional 635 shares during the last quarter. Institutional investors own 96.78% of the company's stock.

Insider Activity

In related news, CFO Andrew Guggenhime sold 8,000 shares of the company's stock in a transaction dated Tuesday, January 21st. The shares were sold at an average price of $86.51, for a total value of $692,080.00. Following the sale, the chief financial officer now owns 109,491 shares in the company, valued at $9,472,066.41. This represents a 6.81 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available at this link. Also, Director Teri Loxam sold 6,250 shares of the company's stock in a transaction dated Wednesday, January 15th. The stock was sold at an average price of $85.11, for a total transaction of $531,937.50. Following the completion of the sale, the director now directly owns 7,175 shares of the company's stock, valued at $610,664.25. The trade was a 46.55 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 46,250 shares of company stock worth $3,840,018. Company insiders own 3.10% of the company's stock.

Remove Ads

Analysts Set New Price Targets

PCVX has been the topic of several analyst reports. The Goldman Sachs Group initiated coverage on shares of Vaxcyte in a research note on Friday, December 20th. They issued a "buy" rating and a $135.00 price objective on the stock. Guggenheim reissued a "buy" rating and issued a $160.00 price objective on shares of Vaxcyte in a research note on Wednesday, March 12th. Finally, Needham & Company LLC reaffirmed a "buy" rating and set a $140.00 price target on shares of Vaxcyte in a research report on Wednesday, February 26th. Nine research analysts have rated the stock with a buy rating, According to MarketBeat.com, Vaxcyte presently has a consensus rating of "Buy" and a consensus price target of $147.50.

Vaxcyte Stock Performance

Shares of NASDAQ PCVX traded up $0.20 during trading on Friday, hitting $74.66. 1,778,118 shares of the company traded hands, compared to its average volume of 933,591. The business's fifty day moving average is $81.41 and its 200 day moving average is $94.10. Vaxcyte, Inc. has a fifty-two week low of $58.10 and a fifty-two week high of $121.06. The firm has a market capitalization of $9.61 billion, a price-to-earnings ratio of -16.23 and a beta of 1.02.

Vaxcyte (NASDAQ:PCVX - Get Free Report) last announced its quarterly earnings data on Tuesday, February 25th. The company reported ($1.02) earnings per share for the quarter, beating the consensus estimate of ($1.16) by $0.14. On average, analysts predict that Vaxcyte, Inc. will post -4.21 EPS for the current year.

Vaxcyte Company Profile

Vaxcyte, Inc, a clinical-stage biotechnology vaccine company, develops novel protein vaccines to prevent or treat bacterial infectious diseases. Its lead vaccine candidate is VAX-24, a 24-valent investigational pneumococcal conjugate vaccine for the prevention of invasive pneumococcal disease. The company also develops VAX-31 to protect against emerging strains and to help address antibiotic resistance; VAX-A1, a novel conjugate vaccine candidate to prevent disease caused by Group A Streptococcus; VAX-PG, a novel protein vaccine candidate targeting keystone pathogen responsible for periodontitis; and VAX-GI to prevent Shigella, a bacterial illness.